rs11057602 - NCOR2
Magnitude 2.2 · 1 study on file
Reported associations
-
Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation - Unknown journal (n.d.) · Unknown authors · PubMed 35213538
ABSTRACT: Large-scale molecular profiling and genotyping provide a unique opportunity to systematically compare the genetically predicted effects of therapeutic targets on the human metabolome. We firstly constructed genetic risk scores for 8 drug targets on the basis that they primarily modify low-density lipoprotein (LDL) cholesterol (HMGCR, PCKS9, and NPC1L1), high-density lipoprotein (HDL) cholesterol (CETP), or triglycerides (APOC3, ANGPTL3, ANGPTL4, and LPL). Conducting mendelian randomisation (MR) provided strong evidence of an effect of drug-based genetic scores on coronary artery disease (CAD) risk with the exception of ANGPTL3. We then systematically estimated the effects of each score on 249 metabolic traits derived using blood samples from an unprecedented sample size of up to
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Bloodwork
-
VLDL cholesterol level Moderate
This genetic variant is associated with elevated medium VLDL cholesterol at genome-wide significance.
Obtain fasting lipid panel including VLDL if not done recently; monitor every 1-2 years.
Discuss with your doctor
-
genetic association with VLDL cholesterol Moderate
Risk allele carriers have elevated medium VLDL levels, an independent cardiovascular risk factor.
Review lipid results with healthcare provider; discuss personalized cardiovascular risk management.